Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $21.38 Average PT from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have received an average rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $21.38.

Several analysts have weighed in on YMAB shares. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. BMO Capital Markets dropped their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Friday, November 15th.

Insider Transactions at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This represents a 14.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 in the last ninety days. 22.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics during the third quarter worth about $44,000. Ameritas Investment Partners Inc. boosted its position in shares of Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after acquiring an additional 1,056 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after buying an additional 3,416 shares during the period. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. Finally, SG Americas Securities LLC acquired a new position in Y-mAbs Therapeutics in the third quarter valued at about $178,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Up 3.1 %

Shares of YMAB opened at $10.41 on Thursday. The company has a 50 day moving average of $13.69 and a two-hundred day moving average of $12.88. The company has a market cap of $466.26 million, a price-to-earnings ratio of -19.28 and a beta of 0.68. Y-mAbs Therapeutics has a twelve month low of $5.29 and a twelve month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. During the same period in the prior year, the business posted ($0.18) EPS. On average, sell-side analysts expect that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.